JP via RSS
Dendreon Perfect Storm
In fact, Bernard Baruch did sell short from time to time, although he did not make money doing so from 1929 to 1932, according to Jim Grant who reviewed his statements.
http://en.wikipedia.org/wiki/Bernard_Baruch
http://www.time.com/time/magazine/article/0,9171,836468,00.html
Dendreon Says Prostate Cancer Treatment Is Effective
DENDREON, CANCER, PROVENGE, BIOTECHNOLOGY, PHARMACEUTICALS
Posted By: Mike Huckman | Reporter
CNBC.com
| 28 Apr 2009 | 02:00 PM ET
Biotechnology firm Dendreon says its unique prostate cancer treatment, Provenge, extended the lives of men in a large clinical trial by more than four months.
Researchers presented the highly anticipated test results Tuesday afternoon at the annual meeting of the American Urological Association in Chicago.
In addition to extending median survival of patients with a certain type of advanced prostate cancer that has spread, Dendreon says it increased the three-year survival rate by 38 percent versus placebo. That’s more than double the three-year survival rate seen in patients on Sanofi-Aventis’ Taxotere.
The company also reports that Provenge resulted in a 22.5 percent reduction in the risk of death compared to placebo, surpassing the 22 percent threshhold Dendreon says it needed to reach.
Provenge is part of an experimental new category of potential cancer-fighters called immunotherapeutics. This is the first big, late-stage clinical trial to show the controversial method of boosting the body’s own defenses to keep tumors in check might actually work.
Dendreon plans to give the test results to the Food and Drug Administration by the end of this year in hopes of winning agency approval in 2010.
